[company_age]3.0[/company_age][employees]1-10 employees[/employees][funding]non_equity_assistance[/funding][description]Lys Therapeutics is a French biopharmaceutical company dedicated to developing innovative therapies for neurological diseases. The company's unique approach focuses on reversing blood-brain barrier dysfunction, a key factor in the progression of many neurological disorders. Lys Therapeutics' lead drug candidate, LYS241, is a monoclonal antibody that targets the interaction between tissue plasminogen activator (tPA) and NMDA receptors, preventing neuroinflammation and neurodegeneration. This innovative mechanism of action sets Lys Therapeutics apart from its competitors, who typically focus on developing drugs that directly target the central nervous system. Lys Therapeutics is currently conducting Phase II clinical trials for LYS241 in stroke, multiple sclerosis, and Parkinson's disease. The company has a strong scientific team with extensive experience in neuroscience and drug development, and is backed by a consortium of leading investors. Lys Therapeutics is headquartered in Lyon, France, with a research and development facility in Caen, France.[/description][ps]First-in-class biotherapies for neurological diseases[/ps]